Latest news with #woundcare
Yahoo
29-05-2025
- Business
- Yahoo
BioStem Technologies to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
POMPANO BEACH, Fla., May 29, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, announces that the company will participate in the Goldman Sachs 46th Annual Global Healthcare Conference, which is taking place in Miami. Jason Matuszewski, the Company's CEO, will participate in a fireside chat and will be available for one-on-one meetings. For conference attendees wishing to schedule a meeting, please contact Noah Agron, VP Corporate Finance and Strategy, at nagron@ Join BioStem's Distribution List & Social Media: To follow the latest developments at BioStem, sign-up to the Company's email distribution list HERE, and follow us on X and LinkedIn. About BioStem Technologies, Inc. (OTC: BSEM):BioStem Technologies is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts. The Company is focused on manufacturing products that change lives, leveraging its proprietary BioREtain® processing method. BioREtain® has been developed by applying the latest research in advanced wound care, focused on maintaining growth factors and preserving tissue structure. BioStem Technologies' quality management system and standard operating procedures have been reviewed and accredited by the American Association of Tissue Banks ('AATB'). These systems and procedures are established per current Good Tissue Practices ('cGTP') and current Good Manufacturing Processes ('cGMP'). Our portfolio of quality brands includes AmnioWrap2™, VENDAJE®, VENDAJE AC®, and VENDAJE OPTIC®. Each BioStem Technologies placental allograft is processed at the Company's FDA registered and AATB accredited site in Pompano Beach, Florida. For more information visit and follow us on X and LinkedIn. Contact BioStem Technologies, Inc.:Phone: 954-380-8342Website: info@ @BSEM_TechFacebook: BioStemTechnologies Investor Relations:Adam HoldsworthE-Mail: adam@ 917-497-9287Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
28-05-2025
- Business
- Yahoo
New £48m wound research centre to open
A university has been awarded £48m to build a world-leading centre for research into wounds. The University of Hull has been given funding to build the Wound Innovation Centre, which it says will research ways to improve life for people with chronic wounds. The NHS spends about £8.3bn a year on wound care - more than obesity and cancer, according to the university. Mat Hardman, professor of wound healing at Hull York Medical School and director of the new centre, said: "Current treatments for wounds are woefully inadequate and we now have an opportunity to change this." The centre will be based at the University of Hull and upgrades are planned at Castle Hill Hospital to provide premium facilities for early-stage wound treatment research. Malcom Burns, 66, from Withernsea, has an unhealed ulcer he got from a leg wound after tripping over a child's go-kart four years ago. Mr Burns said: "There have been times I've been walking around all day and my pain is at a nine or 10 and there's nothing I can do to make it feel better. I can't sleep and it is mentally very damaging." Mr Burns said current treatments do not work but he feels "more able to cope" and "more supported" after taking part in clinical trials with the University of Hull's vascular team. "It is so important that these trials and research into new developments in wound care continue," he said. Mr Burns added: "I believe this new centre will be a real asset to the region and will pioneer new wound care treatment that will bring relief to all those who are suffering. "It will really change lives." The research hub is due to open at the end of the year, a spokesperson for the university said. Listen to highlights from Hull and East Yorkshire on BBC Sounds, watch the latest episode of Look North or tell us about a story you think we should be covering here. Mental health and addiction research hub to open New tech to improve cancer detection and treatment Approval given for £18m medical diagnostic centre University of Hull
BBC News
28-05-2025
- Business
- BBC News
New £48m wound research centre to open in Hull
A university has been awarded £48m to build a world-leading centre for research into University of Hull has been given funding to build the Wound Innovation Centre, which it says will research ways to improve life for people with chronic NHS spends about £8.3bn a year on wound care - more than obesity and cancer, according to the university. Mat Hardman, professor of wound healing at Hull York Medical School and director of the new centre, said: "Current treatments for wounds are woefully inadequate and we now have an opportunity to change this." The centre will be based at the University of Hull and upgrades are planned at Castle Hill Hospital to provide premium facilities for early-stage wound treatment Burns, 66, from Withernsea, has an unhealed ulcer he got from a leg wound after tripping over a child's go-kart four years Burns said: "There have been times I've been walking around all day and my pain is at a nine or 10 and there's nothing I can do to make it feel better. I can't sleep and it is mentally very damaging."Mr Burns said current treatments do not work but he feels "more able to cope" and "more supported" after taking part in clinical trials with the University of Hull's vascular team."It is so important that these trials and research into new developments in wound care continue," he Burns added: "I believe this new centre will be a real asset to the region and will pioneer new wound care treatment that will bring relief to all those who are suffering. "It will really change lives."The research hub is due to open at the end of the year, a spokesperson for the university said. Listen to highlights from Hull and East Yorkshire on BBC Sounds, watch the latest episode of Look North or tell us about a story you think we should be covering here.
Yahoo
26-05-2025
- Health
- Yahoo
Negative Pressure Wound Therapy Market worth US$3.84 billion by 2030 with 6.9% CAGR
DELRAY BEACH, Fla., May 26, 2025 /PRNewswire/ -- The global Negative Pressure Wound Therapy Market, valued at US$2.59 billion in 2024, is forecasted to grow at a robust CAGR of 6.9%, reaching US$2.76 billion in 2025 and an impressive US$3.84 billion by 2030. The increasing prevalence of diabetes, rising cases of traumatic injuries and burn injuries and growing geriatric population drives market growth. Rise in the chronic wound numbers has also facilitated the market. Additionally, favorable government and industry initiatives and reimbursement scene are expected to impact market growth. The growth potential of emerging countries and cost effectiveness of negative pressure wound therapy products also poses an opportunistic factor for market growth. Download PDF Brochure: Browse in-depth TOC on "Negative Pressure Wound Therapy Market" 233 - Tables 46 - Figures 248 - Pages By Based on wound type, the negative pressure wound therapy market is divided into five main segments based on wound type: burns and surgical & open wounds, pressure ulcers, diabetic foot ulcers, venous leg ulcers, and traumatic wounds. The burns and surgical & open wounds segment held the largest market share in 2024. Burns and surgical & open wounds lead the NPWT market because they require advanced wound care solutions to heal the targeted wound properly. These wounds are caused by significant tissue damage, fluid buildup, and can facilitate a high risk of infection. The NPWT devices help by extracting excess fluids, reducing swelling, and creating a maintained environment that supports faster healing and tissue growth. By Based on end users, the negative pressure wound therapy market is divided into home care settings, hospitals, and other end users. Among these, the hospitals segment held the largest market share in 2024. The rising incidence of traumatic injuries and post-operative wounds has further stimulated the need for advanced wound care products in hospitals. Hospital visits for wound care have also increased as a result of the growing geriatric population with chronic illnesses, including diabetes and vascular diseases such as diabetic foot ulcer. Hospitals can treat wounds quickly and effectively due to established wound care protocols, knowledgeable medical staff, and a wide range of negative pressure wound therapy products. By geography, the negative pressure wound therapy market is segmented into five major segments, namely, North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America had the largest market share in the negative pressure wound therapy market in 2024. This is due to the increasing prevalence of diabetes, which leads to diabetic foot ulcers in the geriatric population. Additionally, the huge presence of negative pressure wound therapy manufacturing companies in the region is increasing the market growth. The US has also observed a rise in obesity and road accidents, which has boosted the negative pressure wound therapy market in North America. Request Sample Pages : Prominent players in the negative pressure wound therapy market include, Solventum (US), Smith+Nephew (UK), Cardinal Health (US), Mölnlycke AB (Sweden), Convatec Group PLC (UK), PAUL HARTMANN AG (Germany), Avery Dennison Corporation (US), BenQ Materials Corporation (Taiwan), Double Medical Technology Inc. (China), Advanced Oxygen Therapy Inc. (US), and Carilex Medical (Taiwan). Solventum (US) Solventum split from 3M in April 2024 and established itself. It develops, manufactures, and sells a range of products to meet the needs of clients and patients. For the further expansion of the segments: MedSurg, Purification & Filtration, Dental Solutions, and Health Information Systems, the company is focusing on strategic expansion and innovation. By strengthening its competitive edge through the incorporation of digital skills and material science, the company improves clinical and financial outcomes for healthcare providers. Smith+Nephew (UK): Smith+Nephew (UK) provides a broad portfolio of negative pressure wound therapy products, such as conventional NPWT devices, single-use NPWT devices, and NPWT accessories & consumables. The company also has a strong global market presence, primarily because of its excellent distribution channel. The global presence of the company and the critical nature of its products contribute significantly to the increasing access to healthcare in developed and emerging economies. The company has increased its focus on R&D activities to develop unique and better products. It spent USD 289.0 million, USD 339.0 million, and USD 345.0 million in 2024, 2023, and 2022, respectively, on R&D activities. This strong investment in innovative product development has enabled it to become a well-known player in the negative pressure wound therapy market. Cardinal Health (US) Cardinal Health has a global distribution network and a range of advanced wound care portfolio, making it one of the leaders in the negative pressure wound therapy (NPWT) market. The company provides a broad range of NPWT treatments, including conventional and single use NPWT devices and the required dressings for chronic wound patients. Its wide reach guarantees that these items are widely available to healthcare professionals and patients everywhere. The company expanded its distribution center in Massachusetts, the US, in October 2024. For more information, Inquire Now! Related Reports: Wound Care Biologics Market Advanced Wound Care Market Traditional Wound Care Market Wound Care Market Point of Care Molecular Diagnostics Market Get access to the latest updates on Negative Pressure Wound Therapy Companies and Negative Pressure Wound Therapy Market Size About MarketsandMarkets™: MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe. Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem. The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts. To find out more, visit or follow us on Twitter , LinkedIn and Facebook . Contact:Mr. Rohan SalgarkarMarketsandMarkets™ INC. 1615 South Congress 103, Delray Beach, FL 33445USA: +1-888-600-6441Email: sales@ Our Website: Logo: View original content to download multimedia: SOURCE MarketsandMarkets
Yahoo
22-05-2025
- Business
- Yahoo
Relief Therapeutics Receives FDA Rare Pediatric Disease Designation for RLF-TD011
GENEVA, SWITZERLAND / / May 22, 2025 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY ) (Relief or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) designation to RLF-TD011 for the treatment of epidermolysis bullosa (EB), a rare genetic skin disorder characterized by fragile skin and chronic wounds. The FDA had previously granted Orphan Drug Designation to RLF-TD011 for the same indication. RLF-TD011 is a differentiated, hypotonic acid-oxidizing solution formulated with hypochlorous acid, designed to deliver potent antimicrobial and anti-inflammatory activity while creating a wound microenvironment conducive to healing. The Company previously reported promising clinical findings supporting RLF-TD011's potential to meaningfully advance EB wound care by modulating the wound microbiome and reducing pathogenic colonization without disrupting beneficial bacteria. "The FDA's decision to grant Rare Pediatric Disease designation to RLF-TD011 underscores both the critical need for new options for patients living with EB and the potential of our investigational therapy," said Giorgio Reiner, chief scientific officer of Relief. "We look forward to continued engagement with the FDA and to sharing the next steps in our development plan following our upcoming pre-IND meeting." The FDA grants RPD designation to product candidates targeting serious or life-threatening diseases that primarily affect individuals aged 18 years or younger and impact fewer than 200,000 people in the U.S. Companies that receive marketing approval for an RPD-designated indication may be eligible-subject to certain conditions, including congressional reauthorization of the program for designations granted after December 20, 2024-to receive a Priority Review Voucher (PRV), which grants expedited FDA review for a future marketing application. These vouchers are transferable; in May 2025, a PRV awarded following the approval of a treatment for a rare form of EB was sold for $155 million. ABOUT EPIDERMOLYSIS BULLOSAEpidermolysis bullosa (EB) is a group of rare, inherited connective tissue disorders characterized by extreme skin fragility, leading to blistering and wounds from minor friction or injury. In severe cases, blisters can develop into chronic wounds or form in internal organs such as the mouth or esophagus, leading to painful wounds, recurrent infections, and a deeply impacted quality of life. EB is classified into several major inherited subtypes, each defined by the depth of blister formation within the skin's layers: epidermolysis bullosa simplex (EBS), dystrophic epidermolysis bullosa (DEB), junctional epidermolysis bullosa (JEB) and Kindler syndrome (KS). Treatment is intensive and includes wound care, infection prevention, and pain management. Approximately 500,000 individuals worldwide are affected by EB. ABOUT RLF-TD011RLF-TD011 is a highly pure, stabilized hypochlorous acid solution developed using Relief's proprietary TEHCLO™ technology. With strong antimicrobial properties, RLF-TD011 is a sprayable, self-administered solution for targeted wound application while avoiding skin contact and cross-contamination. Relief's acid-oxidizing solution has previously demonstrated efficacy in accelerating wound closure and reducing infections in certain clinical trials on non-EB wounds. In an investigator-initiated trial (NCT05533866), RLF-TD011 has also shown promising results in infection control and wound healing in EB patients with the most severe forms of the disease. RLF-TD011 aims to address unmet needs in EB care by efficiently controlling infection and inflammation while reducing antibiotic use and easing the intensive, time-consuming wound care routine required by current treatments. The U.S. Food and Drug Administration has granted RLF-TD011 both Orphan Drug and Rare Pediatric Disease designations for EB, and Relief plans to seek Qualified Infectious Disease Product (QIDP) designation for extended market exclusivity. ABOUT RELIEFRelief is a commercial-stage biopharmaceutical company dedicated to advancing treatment paradigms and improving the lives of patients with rare and debilitating diseases. With core expertise in drug delivery systems and drug repurposing, Relief's clinical pipeline includes innovative treatments designed to address critical unmet medical needs in rare dermatological, metabolic and respiratory conditions. The Company has also successfully brought several approved products to market through licensing and distribution partnerships. Headquartered in Geneva, Relief is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB under the symbols RLFTF and RLFTY. For more information, visit CONTACTRELIEF THERAPEUTICS Holding SAJeremy MeinenChief Financial Officercontact@ DISCLAIMERThis press release contains forward-looking statements, which may be identified by words such as "believe," "assume," "expect," "intend," "may," "could," "will," or similar expressions. These statements are based on current plans and assumptions and are subject to risks and uncertainties that could cause actual results, financial condition, performance, or achievements to differ materially from those expressed or implied. Such factors include, but are not limited to, changes in economic conditions, market developments, regulatory changes, competitive dynamics, and other risks or changes in circumstances. This communication is provided as of the date hereof, and Relief undertakes no obligation to update any forward-looking statements contained herein as a result of new information, future events or otherwise. SOURCE: Relief Therapeutics Holding SA View the original press release on ACCESS Newswire
